LabCorp and Mount Sinai to open AI-enabled pathology centre

19 June 2019 (Last Updated December 23rd, 2019 10:22)

LabCorp and the Mount Sinai Health System are set to jointly establish the Mount Sinai Digital and Artificial Intelligence (AI)-enabled Pathology Center of Excellence.

LabCorp and Mount Sinai to open AI-enabled pathology centre
The Philips IntelliSite Pathology Solution at LabCorp’s laboratory. Credit: Koninklijke Philips N.V.

LabCorp and the Mount Sinai Health System are set to jointly establish the Mount Sinai Digital and Artificial Intelligence (AI)-enabled Pathology Center of Excellence.

To be located within Mount Sinai’s Department of Pathology, Molecular and Cell-Based Medicine, the centre will use the Philips IntelliSite Pathology Solution to expand digital capabilities for primary diagnosis as well as consultations across the Mount Sinai Health System.

Every year, the department processes more than 80 million diagnostic tests.

LabCorp Diagnostics Northeast Division senior vice-president William Haas said: “LabCorp and Mount Sinai continue to focus on innovations to enhance the quality and lower the costs of patient care, and we’re pleased to introduce digital pathology to Mount Sinai as the next phase of our collaboration.

“We’ve taken significant steps to enhance laboratory services across the Mount Sinai system since early 2017, and we look forward to continuing to build on those successes to advance LabCorp’s mission and our shared goal to improve health and improve lives.”

So far, LabCorp has implemented the Philips IntelliSite Pathology Solution in four of its laboratories and has further plans to introduce it to additional sites.

Digital pathology will initially be used to interpret genitourinary malignancies, prostate tumours, as well as head and neck cancers.

Mount Sinai pathologists will also use the solution to provide consultations for cases interpreted by LabCorp’s Dianon Pathology speciality laboratory.

Mount Sinai Health System Department of Pathology, Molecular and Cell-Based Medicine chairman Carlos Cordon-Cardo said: “Digital pathology gives us the unprecedented opportunity to expand our services to the community at large, and engage members of our department, considered key opinion leaders in their field, to provide expert diagnostic opinions in complex cases.

“This, in addition to our new predictive AI-based tests, introduces the potential for optimisation of treatment efficacy, and provides the opportunity for improved clinical outcomes.”